Stay tuned for #ASCO2026! OPTIMA trial results — including first insights in premenopausal population — will be presented. These data will contribute to the PATH-FOR-YOUNG / OPTIMA-YOUNG joint analysis on genomic assay–guided chemotherapy de-escalation. #PathForYoung#OptimaYoung
Great news! 🎉 OPTIMA-Young is moving fast towards opening its first centers in France 🇫🇷
The first centers are expected to start enrolling patients in the coming months — an important step forward for the project and for young breast cancer patients. #PathForYoung#OptimaYoung
On May 12th, we celebrated #InternationalNursesDay and honor the dedication, compassion, and resilience of nurses worldwide. Thank you for the incredible impact you make every day in patient care, research, and saving lives. 💙 #NursesDay#PathForYoung
Understanding the patient journey is key to ensure research is aligned with patients and clinicians needs and expectations.
PATH-FOR-YOUNG researchers engaged with a co-creation board for this purpose.
https://t.co/thRaX5idvZ
#PathForYoung
At Path-for-Young, we’re committed to keeping patients informed, supported, and empowered.
🎥New short videos—co-created with our Patient Committee—answer key questions about trial participation and shared decision-making.
Coming soon at: https://t.co/3cv3NNPovC
#PathForYoung
On Jan 28th, the Path-for-Young General Assembly brought together investigators from all participating centers to share updates and plan the next steps toward the study launch. We also heard the latest progress from the OPTIMA trial, now nearing completion.
🌷 Happy International Women’s Day!
At Path-For-Young, we work to improve care and outcomes for young women with breast cancer through research, collaboration and innovation.
Today we celebrate the women in science and the courageous patients who inspire our work.
#PathForYoung
Klineo, a Path-for-Young partner, is expanding to Belgium, Italy & Germany. The free platform helps oncologists quickly identify trials, match patients in under a minute, and track referrals—supporting patient engagement and recruitment across Europe. https://t.co/TmU5rRACLw
Recruitment for the OPTIMA trial closed on 12 Dec 2025, reaching 98.5% of the 4,500-participant target. Around 1,650–1,660 premenopausal patients will contribute to Optima-young analysis. Thanks to all participants and teams for making this milestone possible. #PathforYoung
Path-for-Young partners with the @UniversityLeeds to strengthen health economics and technology assessment. Dr. Alison Smith will co-lead WP8-9, helping ensure personalised breast cancer care is effective, sustainable, and patient-centred. #PathforYoung
On World Cancer Day, we highlight the importance of personalised, equitable care. Path-for-Young is transforming breast cancer care for young women through research, international collaboration, and digital tools like the RESILIENCE app. Learn more: https://t.co/3cv3NNPWla
The Optima-young trial protocol, including the OPTIMIZE digital substudy, has been submitted in Europe. First patients expected Q1 2026, with all sites active by June. This brings us closer to safer, personalised care for young women with HR+/HER2− breast cancer. #PathforYoung
At ESMO 2025, Path-for-Young shared results from a co-creation study within Optima-young. Patient partners and clinicians identified barriers & facilitators in chemo de-escalation trials, shaping the protocol & patient support tools. Read more: https://t.co/KCNE3eUYZ0
As we start the new year, we celebrate the 26 partners across 21 countries behind Path-for-Young. Their expertise in research, digital innovation, patient engagement, and policy helps deliver personalised care, reduce unnecessary chemo, and improve quality of life for young women
As 2025 ends, we thank all patients, researchers, clinicians, and partners who make Path-for-Young possible. Together, we advance personalised care for young women with HR+/HER2− breast cancer. Wishing everyone a joyful holiday season and a happy New Year.
Behind the science: Path-for-Young unites 21 countries & 26 partners with 14 work packages to personalise care for young women with high-risk HR+/HER2– breast cancer. It blends clinical trials, digital tools & patient input to transform treatment. https://t.co/uVByBMzAsA
On Human Rights Day, we recognise health as a fundamental right, including access to personalised cancer care. Path-for-Young aims to reduce unnecessary chemotherapy and improve quality of life for young women with HR+/HER2– breast cancer.
🔍 What if we could change how breast cancer is treated in young women?
Path-for-Young aims to set a new SoC for HR+/HER2– breast cancer with genomic testing, better care, & patient-led design—backed by 21 countries & 26 partners.
Learn more: https://t.co/vLSP4gTUt2
#PathforYoung is more than a trial—it’s a bold initiative to transform care for young women with high-risk HR+/HER2– breast cancer across 21 countries. It targets clinical & societal needs with 7 core goals for personalised, equitable care.
Learn more: https://t.co/Qmv56i5KrN
Last month, @BIGxResearch united sport & science in a women’s rugby tourney in Belgium to support the Optima-Young study! Aure Vanhecke shared how it’s redefining care for premenopausal breast cancer patients, aiming to reduce chemo and focus on personalised endocrine therapy.